U.S. Water Utilities Stock News

NasdaqGM:IMRX
NasdaqGM:IMRXBiotechs

Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress

Immuneering (IMRX) is back on traders’ screens after releasing updated Phase 2a data for atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing higher overall survival and response metrics than standard benchmarks. See our latest analysis for Immuneering. The updated atebimetinib data arrive after a tough recent stretch, with the share price at US$4.73 and a 1 day share price return of 43.22% decline. However, a 1 year total shareholder return of 136.5%...
NYSE:CMA
NYSE:CMABanks

Is Comerica (CMA) Getting Ahead Of Itself After A 55% One Year Share Price Jump

If you are wondering whether Comerica's share price still offers value after a strong run, this review will help you separate sentiment from what the numbers suggest. Comerica's stock last closed at US$92.56, with returns of 6.5% over 7 days, 10.5% over 30 days, 4.4% year to date, 55.1% over 1 year, 57.3% over 3 years and 76.8% over 5 years. Recent market attention on U.S. regional banks has kept Comerica in focus, as investors reassess how interest rate expectations and credit conditions...
NasdaqGM:CVAC
NasdaqGM:CVACBiotechs

Does CureVac’s (CVAC) NASDAQ Exit Quietly Recast Its Risk Profile and Equity Story?

CureVac N.V. recently closed its August 14, 2020 shelf registration in the amount of €3.21 million, covering 26,768,980 common shares for an ESOP-related offering. A day earlier, CureVac was removed from the NASDAQ Composite Index, a change that can influence trading behavior as index-tracking investors rebalance their holdings. We will now examine how CureVac’s removal from the NASDAQ Composite Index may influence its pre-existing investment narrative and risk profile. Uncover the next big...
NYSE:REZI
NYSE:REZIBuilding

Is It Too Late To Consider Resideo Technologies (REZI) After A 63% One-Year Rally?

If you are wondering whether Resideo Technologies is priced attractively or already baking in high expectations, you are in the right place. The stock last closed at US$36.86, with returns of 5.0% over 7 days, 9.8% over 30 days, 4.8% year to date, 63.4% over 1 year, 98.2% over 3 years, and 44.5% over 5 years, which raises fair questions about how much value is now reflected in the share price. Recent coverage has focused on Resideo's position in residential comfort, security and energy...